Latest news
Quince Therapeutics (QNCX) updates S-3 shelf with legal opinion and $498K in costs - Stock TitanStock Titan · Wed, 05 Aug 2026 10:31:10 GMTQuince Therapeutics (QNCX) sees Squadron group report 5.6% ownership stake - Stock TitanStock Titan · Tue, 04 Aug 2026 19:07:14 GMTQNCX Q2'26 Earnings: revenue estimate is 0 USD - TradingViewTradingView · Tue, 04 Aug 2026 11:00:19 GMTQNCX Stockholders Plan to Sell 15.47M Shares Amid Unprofitable B - GuruFocusGuruFocus · Sat, 01 Aug 2026 03:22:30 GMTQuince Therapeutics (QNCX) seeks approval for Orphai merger dilution and $115M PIPE - Stock TitanStock Titan · Fri, 31 Jul 2026 07:00:00 GMTQNCX Initiated by Oppenheimer -- Rating Set to Outperform with $82 Target - GuruFocusGuruFocus · Wed, 29 Jul 2026 17:27:47 GMTOppenheimer Initiates Quince Therapeutics(QNCX.US) With Buy Rating, Announces Target Price $82 - MoomooMoomoo · Wed, 29 Jul 2026 07:00:00 GMT